Dihydropyrimidin-2(1H)-one compounds as S-nitrosoglutathione reductase inhibitors

A method of treating asthma, cystic fibrosis or chronic obstructive pulmonary disease (COPD), which comprises administering to a patient in need thereof a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof:

• wherein
• X is selected from the group consisting of aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl, each having 6 members or less in the ring;
• Y is selected from the group consisting of aryl, substituted aryl, heteroaryl, substituted heteroaryl, C4-C6 cycloalkyl, substituted C4-C6 cycloalkyl, heterocyclyl, and substituted heterocyclyl;
• Z is selected from the group consisting of O, S and NR7;
• R1, R2 and R7 are independently selected from the group consisting of hydrogen, and C1-C6 alkyl;
• R3 is selected from the group consisting of hydrogen, nitro, cyano, carboxy, carbamoyl, methylsulfonamido, fluoro, chloro, bromo, hydroxy, methylsulfonyl, and methylsulfinyl, isoxazol-4-yl, C1-C6 alkoxy, —C(NH)NHOH, sulfonic acid, and acetyl;
• R4 is selected from the group consisting of hydroxy, carboxy, and tetrazol-5-yl;
• R5 is selected from the group consisting of hydrogen, hydroxy, carboxy, chloro, fluoro, cyano, —O(CH2)1-6NMe2, C1-C6alkyl, —O(CH2)1-6OCH3, —O(CH2)1-6OH, acetyl, CF3, and C1-C6 alkoxy;
• and
• R6 is selected from the group consisting of hydrogen and hydroxy.